Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: dendritic cell vaccine - OXvax

Drug Profile

Research programme: dendritic cell vaccine - OXvax

Alternative Names: CD141+XCR1+dendritic cells vaccine - OXvax; Off-the-shelf semi-allogeneic cancer vaccine - OXvax

Latest Information Update: 26 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OxVax
  • Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 21 Apr 2021 Preclinical trials in Solid tumours in United Kingdom (Parenteral) prior to April 2021
  • 21 Apr 2021 OXvax plans clinical trials for Solid tumours in the UK
  • 03 Aug 2017 OXvax has patent protection for OXvax technology in major jurisdictions worldwide, and patent filed worldwide (WO2017129981A1) for invention of induced pluripotent stem cells (iPSCs) produced from source dendritic cells (DCs), synthetic DCs re-differentiated the iPSCs, and methods for making and methods of using the iPSCs and DCs of the invention. The patent is pending protection in US, China, and Europe
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top